MTVA — MetaVia Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1638287 ·
Last close
$1.25
Market Cap
$8.24M
52W High
$13.42
52W Low
$0.97
ADV30
150,963
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -4,693,000 | -4,623,000 | 9,554,000 | 8,778,000 | 7,143,000 |
| Jun 2026 | 0 | — | -5,385,000 | -5,316,000 | 13,271,000 | 12,634,000 | 6,449,000 |
| Mar 2026 | 0 | — | -4,025,000 | -3,823,000 | 14,388,000 | 13,731,000 | 5,315,000 |
| Dec 2025 | 0 | — | -2,046,000 | -1,930,000 | 11,123,000 | 10,278,000 | 5,790,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,835,000
Investing CF
$-2,000
Financing CF
$10,880,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.10
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-157,969,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-14,931,000
Pretax Income TTM
$-14,446,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -13,708,000 | -12,973,000 | 11,123,000 | 5,790,000 | 5,333,000 | -15,701,000 |
| Dec 2024 | 0 | -28,809,000 | -27,592,000 | 16,260,000 | 8,329,000 | 7,931,000 | -24,710,000 |
| Dec 2023 | 0 | -15,886,000 | -12,470,000 | 22,781,000 | 6,096,000 | 16,685,000 | -10,799,000 |
| Dec 2022 | 0 | -11,418,000 | -13,967,000 | 33,534,000 | 11,784,000 | 21,750,000 | -11,712,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$-4,022,000
NetIncome TTM
$-14,446,000
OpCashFlow TTM
—
Assets (Latest)
$13,271,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KYNB | KYNTRA BIO, INC. | $8.26M | $2.04 | — |
| AEMD | AETHLON MEDICAL INC | $8.17M | $5.08 | — |
| VTGN | Vistagen Therapeutics, Inc. | $8.34M | $0.19 | — |
| CALC | CalciMedica, Inc. | $8.41M | $1.22 | — |
| DARE | Dare Bioscience, Inc. | $8.44M | $0.43 | — |
News headlines (Yahoo Finance, 1h cache)
MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
2026-11-17 13:31 · Yahoo
MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026
2026-11-16 13:31 · Yahoo
MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-13 13:31 · Yahoo
MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial
2026-11-12 13:31 · Yahoo
MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026
2026-11-09 13:31 · Yahoo
MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data
2026-11-05 13:55 · Yahoo
MTVA: 68% Liver Fat Reduction in Phase 1 Part 3B Trial of DA-1726; Plans Shift Toward MetALD and ALD Development
2026-11-05 12:00 · Yahoo
MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
2026-10-28 12:31 · Yahoo
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
2026-10-13 12:31 · Yahoo
MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction
2026-09-10 12:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.